Stories
Zydus and MSN Laboratories Launch First Generic Adempas in US Market
N
News18•06-10-2026, 00:45
Zydus and MSN Laboratories Launch First Generic Adempas in US Market
- •Zydus Lifesciences has partnered with MSN Laboratories to launch the first generic version of Adempas (Riociguat tablets) in the United States.
- •The generic launch covers Riociguat tablets across all five strengths ranging from 0.5 mg to 2.5 mg.
- •Riociguat is prescribed for adults dealing with persistent or recurrent chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension.
- •Global sales of the brand-name drug Adempas reached approximately USD 850 million in 2025 according to Bayer's Annual Report cited in the filing.
Key Questions Answered
Zydus Lifesciences, in partnership with MSN Laboratories, has launched Riociguat tablets as the first generic version of Adempas in the US market across all five strengths ranging from 0.5 mg to 2.5 mg.
Riociguat is indicated for treating adults with persistent or recurrent chronic thromboembolic pulmonary hypertension after surgery or inoperable cases, as well as pulmonary arterial hypertension to improve exercise capacity and delay clinical worsening.
According to Bayer's Annual Report 2025 cited in the regulatory filing, global sales of Adempas reached approximately USD 850 million in 2025.
